

**ASX Announcement**  
**29 July 2024 (Melbourne, Australia)**  
**Optiscan Imaging Ltd (ASX:OIL)**

## **Major Development Milestone Delivered in Optiscan's Telepathology Platform**

**Optiscan and its partner ProLucid have beta tested the functionality of their cloud-based telepathology platform, opening the way for enhanced patient imaging in remote scenarios**

### **Highlights**

- Optiscan has completed the beta phase of its cloud-based telepathology platform in collaboration with partner ProLucid Technologies.
- Key deliverables in the beta phase include the ability to register, authenticate, and securely connect devices to the cloud platform.
- The telepathology platform is designed to enhance digital pathology capabilities, allowing remote users to make immediate, informed decisions.
- The platform leverages Optiscan's confocal imaging technology to enable real-time, remote collaboration on patient imaging sessions.

**Optiscan Imaging Limited (ASX:OIL) ('Optiscan' or 'The Company')** is pleased to announce the successful completion of the beta phase of its innovative cloud-connected telepathology platform, developed in partnership with ProLucid Technologies. This development represents a significant advancement in digital pathology, enabling real-time, remote collaboration on patient imaging sessions.

### **The platform utilises Optiscan's unique MedTech**

Leveraging Optiscan's confocal imaging technology, which natively generates digital pathology data, the telepathology platform empowers remote pathologists and clinicians to collaborate in real-time during patient imaging sessions. This collaborative approach facilitates immediate, informed decision-making at the point of care, ultimately improving patient outcomes.

The platform streamlines the telepathology workflow with secure device-to-cloud connectivity and a dedicated web portal. At the patient's side, Optiscan's device captures real-time confocal images and transmits them securely to the cloud platform. Remote pathologists can seamlessly join the imaging session on a computer terminal, view and flag images, and communicate observations directly with the clinician performing the imaging – all in real-time. The platform also allows for offline review and annotation of captured images, with detailed report generation planned for a future iteration. Patient data privacy and secure user access are protected with the architecture adhering to the highest regulatory and cybersecurity standards.

## The beta testing was successful on multiple fronts

Key deliverables in the beta phase included the ability to register, authenticate, and securely connect devices to the cloud platform. As a package, these achievements demonstrate that Optiscan devices can now stream images to the cloud platform as they are acquired, enabling real-time visualization by remote users. The session data can also be pushed to cloud storage for post-session review.

Proof of concept for post-session review, image annotation, and session data comparison workflows have also been successfully implemented, and development of the commercial version is currently underway. User authentication, data transmission latency, patient privacy protection, data encryption, synchronization, and management have been implemented, ensuring compliance with stringent cybersecurity requirements.

This development is a further evolution in Optiscan's imaging technology, allowing real-time collaboration and quick decision-making between clinicians and pathologists all over the world. Historically the access patients and clinicians had to sophisticated pathology insights has relied on the expertise available within the hospitals and medical facilities in which they operate. By leveraging cloud-based technology, Optiscan aims to remove those limitations and bring sophisticated digital pathology to anyone, anywhere, anytime. This has great potential for telehealth consultations in regional, rural, and remote areas where pathology expertise is often unavailable, and can help improve patient outcomes, no matter where they live.

**Optiscan CEO and Managing Director, Dr. Camile Farah, commented:** *“We are thrilled with the outcomes from the beta phase testing of our telepathology platform, which leverages Optiscan’s confocal imaging technology to transform digital pathology. This key stage of the platform’s development journey would not have been possible without the efforts of Prolucid Technologies, our partner in this exciting project. The beta testing demonstrated that we have met our goal of creating a cloud-connected telepathology platform that effectively bridges the gap between imaging and remote diagnostics, providing a seamless, secure, and efficient workflow.”*

*“This achievement makes the platform a potential game changer for telehealth consultations for patients who live outside of capital city areas. In the past, regional, rural and remote health facilities have lacked the dedicated pathology expertise limiting collaboration and immediate decision-making between clinicians and pathologists. Our platform provides a way for isolated communities to tap into pathology expertise previously not available to them due to limited medical infrastructure or difficulties in attracting health care professionals. Our telepathology-enabled imaging solutions democratize pathology services and high quality patient care.”*

*“With the successful beta testing phase complete, we have already ramped up efforts to create a commercial version of our telepathology platform and now look forward to its implementation in clinical settings. Our aim is to initially implement a minimal viable telepathology platform, with further enhancements and features to be developed in subsequent phases.”*

– ends –

This announcement has been authorised for release by the Board of Optiscan.

### **For further information, please contact:**

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

**T:** +61 3 9538 3333

**E:** [ceo@optiscan.com](mailto:ceo@optiscan.com)

Media & Investor Enquiries

The Capital Network

Julia Maguire

**T:** +61 2 8999 3699

**E:** [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

### **About Optiscan**

Optiscan Imaging Ltd (ASX:OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit [www.optiscan.com](http://www.optiscan.com) or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

### **Disclaimer**

*All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.*